Protein induced by vitamin K absence or antagonist‐II (PIVKA‐II), also called des‐c‐carboxy prothrombin (DCP) initially identified in 1984 as a specific biomarker for HCC [5], has emerged as a promising diagnostic and prognostic tool for HCC surveillance, including in early‐stage and AFP‐negative disease [6, 7]. This evidence concerns the gene ACE and hepatocellular carcinoma.